Heat Biologics Stock Financials

HTBX -  USA Stock  

USD 2.90  0.07  2.36%

Understanding current and past Heat Biologics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Heat Biologics' financial statements are interrelated, with each one affecting the others. For example, an increase in Heat Biologics' assets may result in an increase in income on the income statement. Because of this, it is necessary to analyze all of Heat Biologics' financials over time to get the whole picture.
Heat Biologics Average Assets are fairly stable at the moment as compared to the past year. Heat Biologics reported Average Assets of 100.59 Million in 2021. Average Equity is likely to rise to about 96.9 M in 2022, whereas Earnings Before Interest Taxes and Depreciation Amortization EBITDA are likely to drop (23.7 M) in 2022.
We strongly advise to harness analysis of Heat Biologics fundamentals to see if markets are presently mispricing the company. We have analyzed thirty-three available reported financial drivers for Heat Biologics, which can be compared to its competitors. To make sure the equity is not overpriced, please check out all Heat Biologics financials, including its number of shares shorted, current ratio, current liabilities, as well as the relationship between the ebitda and beta . Please also validate Heat Biologics price to book to confirm the company can sustain itself down the road. Use Heat Biologics to protect your portfolios against small market fluctuations. The stock experiences an unexpected downward movement. The market is reacting to new fundamentals. Check odds of Heat Biologics to be traded at $2.78 in 90 days.

Heat Biologics Fundamentals 

With this module, you can analyze Heat Biologics financials for your investing period. You should be able to track the changes in Heat Biologics individual financial statements over time to develop the understanding of its risk, liquidity, profitability, or other critical and vital indicators.
The fundamental analysis of Heat Biologics is a critical element in measuring its lifeblood. The essential information of the day-to-day investment outlook for Heat Biologics includes many different criteria found on its balance sheet. For example, investors should never minimize Heat Biologics' ability to pay suppliers or employees on time, making sure interest payments are not accumulating or correctly timing where and how to re-invest extra cash. Any individual investor needs to monitor Heat Biologics' cash flow, debt, and profitability to effectively and accurately make more informed decisions on whether to invest in Heat Biologics.

Heat Biologics Cash

Chance Of Financial Distress
Less than 31
Heat Biologics has less than 31 (%) percent chance of experiencing financial distress in the next two years of operations. The calculation of odds of distress for Heat Biologics stock is tightly coupled with the Probability of Bankruptcy. It complements the equity performance score by supplying investors with insight into company financials without requiring them to know too much about all of the complex accounting and financial indicators surrounding the entity. More Info
The data published in Heat Biologics' official financial statements usually reflect Heat Biologics' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Heat Biologics. For example, before you start analyzing numbers published by Heat Biologics accountants, it's critical to develop an understanding of what Heat Biologics' liquidity, profitability, and earnings quality are in the context of the Healthcare space in which it operates.
Please note, the presentation of Heat Biologics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Heat Biologics' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Heat Biologics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Heat Biologics. Please utilize our Beneish M Score to check the likelihood of Heat Biologics' management to manipulate its earnings.

Heat Biologics Company Summary

Heat Biologics competes with Brickell Biotech. Heat Biologics, Inc., a biopharmaceutical company, engages in the development of immunotherapies to activate patients immune system against cancer through T-cell activation and expansion. The company was incorporated in 2008 and is headquartered in Morrisville, North Carolina. Heat Biologics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs people.
Healthcare, Biotechnology
InstrumentUSA Stock View All
ExchangeNASDAQ Exchange
LocationNorth Carolina; U.S.A
Business Address627 Davis Drive
Phone919 240 7133
CurrencyUSD - US Dollar
You should never invest in Heat Biologics without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Heat Biologics Stock, because this is throwing your money away. Analyzing the key information contained in Heat Biologics' financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.

Heat Biologics Key Financial Ratios

Generally speaking, Heat Biologics' financial ratios allow both analysts and investors to convert raw data from Heat Biologics' financial statements into concise, actionable information that can be used to evaluate the performance of Heat Biologics over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Heat Biologics reports annually and quarterly.

Heat Biologics Key Balance Sheet Accounts

201720182019202020212022 (projected)
Total Assets20.19 M37.76 M25.96 M124.19 M142.82 M154.1 M
Current Assets11.75 M28.71 M15.21 M113.79 M130.86 M141.19 M
Assets Non Current8.44 M9.05 M10.75 M10.4 M11.96 M12.9 M
Cash and Equivalents9.84 M22.51 M9.43 M11.05 M12.71 M11.48 M
Shareholders Equity7.37 M30.29 M13.57 M116.24 M133.68 M144.23 M
Total Liabilities14.41 M7.52 M12.8 M8.7 M10.01 M9.39 M
Current Liabilities10.34 M4.87 M8.44 M3.66 M4.21 M4.81 M

Heat Biologics Key Income Statement Accounts

An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket. The other reason investors look at the income statement is to determine what Heat Biologics' earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
201720182019202020212022 (projected)
Consolidated Income(12.41 M)(16.59 M)(20.38 M)(26.38 M)(23.74 M)(24.37 M)
Gross Profit1.52 M5.79 M3.05 M2.95 M3.39 M3.37 M
Net Income(11.84 M)(15.73 M)(20.02 M)(26.05 M)(23.44 M)(24.06 M)
Operating Expenses14.64 M23.26 M23.18 M27.87 M32.05 M26.17 M
Operating Income(13.12 M)(17.46 M)(20.13 M)(24.93 M)(22.43 M)(24.2 M)
Revenues1.52 M5.79 M3.05 M2.95 M3.39 M3.37 M

Heat Biologics Key Cash Accounts

Cash flow analysis captures how much money flows into and out of Heat Biologics. It measures of how well Heat Biologics is doing because it can show the actual money that comes into and out of the company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money Heat Biologics brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money Heat Biologics had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what Heat Biologics has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
201720182019202020212022 (projected)
Capital Expenditure(61.38 K)(593.57 K)(155.56 K)(335.8 K)(302.22 K)(326.08 K)
Depreciation Amortization and Accretion134.08 K237.32 K271.62 K428.75 K493.06 K531.99 K
Net Cash Flow or Change in Cash and Cash Equivalents1.82 M12.39 M(13.11 M)1.89 M1.7 M1.4 M
Issuance Purchase of Equity Shares8.77 M40.12 M19.05 K121.45 M139.67 M150.69 M
Net Cash Flow from Financing8.77 M40.12 M19.05 K119.33 M137.23 M148.06 M
Net Cash Flow from Investing(530.18 K)(6.16 M)(294 K)(95.42 M)(85.88 M)(88.14 M)
Net Cash Flow from Operations(6.4 M)(21.71 M)(12.84 M)(22.02 M)(19.82 M)(21.38 M)
Effect of Exchange Rate Changes on Cash(14.25 K)145.76 K(1.77 K)3.75 K4.32 K4.43 K
Share Based Compensation689.13 K788.66 K3.27 M6.38 M7.33 M7.91 M

Heat Biologics Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Heat Biologics's current stock value. Our valuation model uses many indicators to compare Heat Biologics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Heat Biologics competition to find correlations between indicators driving Heat Biologics's intrinsic value. More Info.
Heat Biologics is rated # 2 in total asset category among related companies. It is one of the top stocks in return on asset category among related companies . Average Assets is likely to rise to about 108.5 M in 2022. Tangible Asset Value is likely to rise to about 152.3 M in 2022. Comparative valuation analysis is a catch-all model that can be used if you cannot value Heat Biologics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Heat Biologics' Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Heat Biologics' earnings, one of the primary drivers of an investment's value.

Heat Biologics Systematic Risk

Heat Biologics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Heat Biologics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Beta measures systematic risk based on how returns on Heat Biologics correlated with the market. If Beta is less than 0 Heat Biologics generally moves in the opposite direction as compared to the market. If Heat Biologics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Heat Biologics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Heat Biologics is generally in the same direction as the market. If Beta > 1 Heat Biologics moves generally in the same direction as, but more than the movement of the benchmark. View also all equity analysis or get more info about beta statistic functions indicator.

About Heat Biologics Financials

What exactly are Heat Biologics Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include Heat Biologics' income statement, its balance sheet, and the statement of cash flows. Potential Heat Biologics investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Heat Biologics investors may use each financial statement separately, they are all related. The changes in Heat Biologics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Heat Biologics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.
 2019 2020 2021 2022 (projected)
Current Assets15.21 M113.79 M130.86 M141.19 M
Total Assets25.96 M124.19 M142.82 M154.1 M
There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines that you should keep in mind when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase year after year due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt to equity ratio because this number will tell you how much risk it has. If a company such as Heat Biologics is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to try and figure out if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that net revenue of Heat Biologics grown by more than 25% over the last five years, then there is a good chance that it will continue growing at least by 20% or more each year. On the other hand, if you see that net revenue has only grown by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it.

Heat Biologics January 19, 2022 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Heat Biologics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Heat Biologics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Heat Biologics based on widely used predictive technical indicators. In general, we focus on analyzing Heat Biologics Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Heat Biologics's daily price indicators and compare them against related drivers.
Information Ratio(0.20)
Maximum Drawdown25.49
Value At Risk(9.04)
Potential Upside3.57
Please check Risk vs Return Analysis. Note that the Heat Biologics information on this page should be used as a complementary analysis to other Heat Biologics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.

Complementary Tools for Heat Biologics Stock analysis

When running Heat Biologics price analysis, check to measure Heat Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Heat Biologics is operating at the current time. Most of Heat Biologics' value examination focuses on studying past and present price action to predict the probability of Heat Biologics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Heat Biologics' price. Additionally, you may evaluate how the addition of Heat Biologics to your portfolios can decrease your overall portfolio volatility.
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Is Heat Biologics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Heat Biologics. If investors know Heat Biologics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Heat Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Heat Biologics is measured differently than its book value, which is the value of Heat Biologics that is recorded on the company's balance sheet. Investors also form their own opinion of Heat Biologics' value that differs from its market value or its book value, called intrinsic value, which is Heat Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Heat Biologics' market value can be influenced by many factors that don't directly affect Heat Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Heat Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine Heat Biologics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Heat Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.